Industry
Biotechnology
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Loading...
Open
11.82
Mkt cap
232M
Volume
2.1M
High
12.95
P/E Ratio
-2.14
52-wk high
21.66
Low
11.30
Div yield
N/A
52-wk low
6.50
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:37 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 3:38 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 6:51 pm
Portfolio Pulse from Patricio Liddle
June 26, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 11:45 am
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 4:28 pm
Portfolio Pulse from Jelena Martinovic
June 18, 2024 | 4:48 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.